Who are we ?

Our team

Multidisciplinary expertise

From fundamental research to clinical development

The scientific discoveries behind the creation of AmyPore are the fruit of the work of two internationally recognised university professors, Prof. Nouara Yahi (Aix-Marseille University) and Prof. Jacques Fantini (Aix-Marseille University and Institut Universitaire de France), who together have more than 300 publications in leading scientific journals.

Around them, AmyPore has brought together the skills needed to develop its platform and to take its therapeutic peptides from research to the clinic: molecular neuroscience, biochemistry of biological membranes, hospital neurology, pharmaceutical development and corporate leadership.

The team brings together researchers trained at Aix-Marseille University, Harvard Medical School and the University of Montreal, a hospital neurologist at Toulouse University Hospital specialising in cognitive disorders, an executive who served as Vice President of Pfizer Inc. and a finance expert who served as Chief Executive Officer of an international group. This complementarity between fundamental research, clinical practice, industrial experience and corporate governance guides every stage of our programme’s development.

Portrait de Dr. Anaïs Aulas
Dr. Anaïs Aulas (Ph.D.)
Project Leader
A doctor in biochemistry from the University of Montreal, Anaïs Aulas was a researcher at Harvard Medical School and then at the Marseille Cancer Research Centre. Thirteen years of fundamental and translational research in neuroscience, oncology and cellular stress. She leads AmyPore’s growth and operational development.in
mohan-sidi-said
Mohand Sidi Saïd
Strategic advisor
A former vice-president of Pfizer Inc., where he was one of the group’s three presidents, Mohand Sidi Saïd sat on the “G7” committee, responsible for research and development with an annual budget of 7 billion dollars, as well as for licensing and acquisitions. He built the group’s leadership in demanding markets, from Japan to China and from Africa to Latin America, and contributed to the partnership with Eisai Japan on Aricept as well as to the acquisition of Warner-Lambert. He chairs AmyPore’s strategic committee.in
Portrait de Xavier Urbain
Xavier Urbain
Strategic advisor
Directeur général du groupe CEVA Logistics de 2014 à 2019, Xavier Urbain a exercé des fonctions de direction dans la logistique internationale : comité exécutif de Kuehne & Nagel, direction générale de Hays Logistics et conseil d’administration de Hays PLC, direction générale d’ACR. Il a présidé les conseils d’administration de Socotec et de Caldic, siège à celui de LKQ Corporation et préside HL Holding. Diplômé en commerce et finance, il est conseiller stratégique d’AmyPore.in
Portrait de Prof. Jacques Fantini
Prof. Jacques Fantini (Ph.D.)
CSO
Member of the Scientific Committee
A university professor of exceptional class, a member of the Institut Universitaire de France and of the Académie des Sciences, Lettres et Arts de Marseille, Jacques Fantini is the author of more than 200 scientific publications. A world-renowned specialist in molecular modelling applied to membrane systems, he is co-inventor of the patented AmyP53 molecule, whose intellectual property he holds together with Prof. Nouara Yahi.in
nouara-yahi
Prof. Nouara Yahi (Ph.D.)
Member of the Scientific Committee
A university professor and the author of more than 120 scientific publications, Nouara Yahi has 35 years of research (INSERM, CNRS) and teaching in virology and molecular neuroscience at Aix-Marseille University. Her main line of research has been to determine how distinct pathologies result from common molecular mechanisms involving lipid-protein interactions within cell membranes. Co-inventor of AmyP53, she holds the patent together with Prof. Jacques Fantini.in
Portrait de Prof. Jérémie Pariente
Prof. JEREMIE PARIENTE (M.D. Ph.D.)
Expert neurologist
A university professor and hospital practitioner at Toulouse University Hospital, Jérémie Pariente heads the department dedicated to cognitive and movement disorders. A board member of the French Neurology Society, he has led numerous studies on Alzheimer’s disease and advises AmyPore on the setting up of clinical trials.in
Portrait de Dr. Coralie Di Scala
Dr. Coralie Di Scala (Ph.D.)
Member of the Scientific Committee
A doctor in molecular neuroscience, Coralie Di Scala defended a thesis on amyloid pores in 2014. Her expertise in this field is internationally recognised. She currently heads a neuroscience research team in Helsinki, Finland.in
henri-chahinian
Dr. Henri Chahinian (Ph.D.)
Chairman of the Scientific Committee
A senior lecturer at Aix-Marseille University, Henri Chahinian is an internationally recognised specialist in the biochemistry of lipids and proteins of biological membranes. He has forty years of experience in fundamental and applied research.in
Portrait de Mélodie Bricha
Mélodie Bricha
Investor Relations
Trained in business, Mélodie Bricha has held international commercial roles in Paris, London, Venice and New York. An entrepreneur, she runs her own digital venture and invests personally in international start-ups.in
driss_fantini
Driss Fantini
President
A graduate of the Grande École Programme at Kedge Business School and of the Pépite-PACA entrepreneurship programme at Aix-Marseille University, Driss Fantini founded AmyPore in 2018. He led the European H2020 SME Phase 1 programme AmInnovation and oversaw the entire regulatory preclinical programme for AmyP53. He is the company’s Chairman.in